Home Cart Sign in  
Chemical Structure| 538-71-6 Chemical Structure| 538-71-6

Structure of Domiphen bromide
CAS No.: 538-71-6

Chemical Structure| 538-71-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Domiphen bromide is a chemical antiseptic and a quaternary ammonium compound, used as a cationic surfactant.

Synonyms: Domiphen (bromide); NSC-39415

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Domiphen bromide

CAS No. :538-71-6
Formula : C22H40BrNO
M.W : 414.46
SMILES Code : CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1.[Br-]
Synonyms :
Domiphen (bromide); NSC-39415
MDL No. :MFCD00011769
InChI Key :OJIYIVCMRYCWSE-UHFFFAOYSA-M
Pubchem ID :10866

Safety of Domiphen bromide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Listeria monocytogenes ScottA 0.8 µM (0.3 µg/mL) 24 hours Evaluate the synergistic antibacterial activity of miconazole and domiphen bromide, showing synergy (FIC ≤0.5). Antibiotics (Basel). 2024 Oct 10;13(10):949
Bacillus cereus ATCC 7004 2.4 µM (1.0 µg/mL) 24 hours Evaluate the synergistic antibacterial activity of miconazole and domiphen bromide, showing synergy (FIC ≤0.5). Antibiotics (Basel). 2024 Oct 10;13(10):949
Streptococcus dysgalactiae ATCC 10706 1.3 µM (0.6 µg/mL) 24 hours Evaluate the synergistic antibacterial activity of miconazole and domiphen bromide, showing synergy (FIC ≤0.5). Antibiotics (Basel). 2024 Oct 10;13(10):949
Streptococcus pyogenes ATCC 12358 1.0 µM (0.4 µg/mL) 24 hours Evaluate the synergistic antibacterial activity of miconazole and domiphen bromide, showing additivity (0.5 < FIC ≤1.0). Antibiotics (Basel). 2024 Oct 10;13(10):949
Enterococcus faecium LMG 8148 20.4 µM (8.5 µg/mL) 24 hours Evaluate the synergistic antibacterial activity of miconazole and domiphen bromide, showing additivity (0.5 < FIC ≤1.0). Antibiotics (Basel). 2024 Oct 10;13(10):949
Staphylococcus epidermidis CL7 1.7 µM (0.7 µg/mL) 24 hours Evaluate the synergistic antibacterial activity of miconazole and domiphen bromide, showing synergy (FIC ≤0.5). Antibiotics (Basel). 2024 Oct 10;13(10):949
Staphylococcus aureus MRSA 25.1 µM (10.4 µg/mL) 24 hours Evaluate the synergistic antibacterial activity of miconazole and domiphen bromide, showing synergy (FIC ≤0.5). Antibiotics (Basel). 2024 Oct 10;13(10):949
Staphylococcus epidermidis SE40 10.6 µM (4.4 µg/mL) 24 hours Evaluate the synergistic antibacterial activity of miconazole and domiphen bromide, showing synergy (FIC ≤0.5). Antibiotics (Basel). 2024 Oct 10;13(10):949
Staphylococcus aureus SH1000 10.5 µM (4.4 µg/mL) 24 hours Evaluate the synergistic antibacterial activity of miconazole and domiphen bromide, showing synergy (FIC ≤0.5). Antibiotics (Basel). 2024 Oct 10;13(10):949
Acinetobacter baumannii RD5SR3 1.6 µM (0.7 µg/mL) 24 hours Evaluate the synergistic antibacterial activity of miconazole and domiphen bromide, showing synergy (FIC ≤0.5). Antibiotics (Basel). 2024 Oct 10;13(10):949
Plasmodium falciparum 3D7 20 µM 48 hours To evaluate the inhibitory effect of DB on Plasmodium growth, results showed significant growth inhibition observed 8 hours after DB treatment Pharmaceutics. 2022 Jun 22;14(7):1320
Candida albicans ATCC 10231 1 μg/mL 24 hours Evaluate the inhibitory effect of the drug combination on C. albicans biofilm formation, showing significant reduction in biofilm formation. Front Microbiol. 2024 May 30;15:1341316
Escherichia coli 8099 1 μg/mL 24 hours Evaluate the inhibitory effect of the drug combination on E. coli biofilm formation, showing significant reduction in biofilm formation. Front Microbiol. 2024 May 30;15:1341316
Candida albicans SC5314 and Candida glabrata BG2 planktonic cells 25 μM 24 hours Combined with MCZ, significantly reduced the number of viable planktonic cells Antimicrob Agents Chemother. 2020 Sep 21;64(10):e01296-20
Candida auris biofilms 37.5 μM 24 hours Combined with MCZ, significantly reduced the number of viable biofilm cells Antimicrob Agents Chemother. 2020 Sep 21;64(10):e01296-20
Candida glabrata BG2 biofilms 25 μM 48 hours Combined with MCZ, significantly reduced the number of viable biofilm cells Antimicrob Agents Chemother. 2020 Sep 21;64(10):e01296-20
Candida albicans Tansir_082 and Tansir_121B biofilms 12.5 μM 24 hours Combined with MCZ, significantly reduced the number of viable biofilm cells in resistant strains Antimicrob Agents Chemother. 2020 Sep 21;64(10):e01296-20
Candida albicans SC5314 biofilms 37.5 μM 24 hours Combined with miconazole (MCZ), significantly reduced the number of viable biofilm cells (1000-fold reduction) Antimicrob Agents Chemother. 2020 Sep 21;64(10):e01296-20
CHO cells 9 nM 5 minutes To investigate the inhibitory effect of Domiphen bromide on HERG channel currents, results showed it inhibited HERG channel currents in a dose-dependent manner with an IC50 value of 9 nM. Eur J Pharmacol. 2014 Aug 15;737:202-9
Staphylococcus aureus ATCC 6538 1 μg/mL 24 hours Evaluate the inhibitory effect of the drug combination on S. aureus biofilm formation, showing significant reduction in biofilm formation. Front Microbiol. 2024 May 30;15:1341316

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Vulvovaginal candidiasis model Vaginal administration 0.144% Twice daily for 6 consecutive days Combination treatment significantly reduced infection burden and fungal infiltration in tissues compared to MCZ alone Antimicrob Agents Chemother. 2020 Sep 21;64(10):e01296-20

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.41mL

0.48mL

0.24mL

12.06mL

2.41mL

1.21mL

24.13mL

4.83mL

2.41mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories